

# Anton Forsberg MorÃ©n

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1816198/publications.pdf>

Version: 2024-02-01

44  
papers

3,573  
citations

218677

26  
h-index

254184

43  
g-index

45  
all docs

45  
docs citations

45  
times ranked

4544  
citing authors

#	ARTICLE	IF	CITATIONS
1	PET imaging of amyloid deposition in patients with mild cognitive impairment. <i>Neurobiology of Aging</i> , 2008, 29, 1456-1465.	3.1	611
2	Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. <i>Brain</i> , 2006, 129, 2856-2866.	7.6	587
3	Clinical Validation of <sup>18</sup> F-AZD4694, an Amyloid- $\beta$ -Specific PET Radioligand. <i>Journal of Nuclear Medicine</i> , 2012, 53, 415-424.	5.0	204
4	Brain glial activation in fibromyalgia – A multi-site positron emission tomography investigation. <i>Brain, Behavior, and Immunity</i> , 2019, 75, 72-83.	4.1	186
5	A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 104-114.	6.4	170
6	Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 198.e1-198.e14.	3.1	135
7	Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. <i>Annals of Neurology</i> , 2008, 63, 621-631.	5.3	124
8	Test-retest reproducibility of [11C]PBR28 binding to TSPO in healthy control subjects. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 173-183.	6.4	106
9	High PIB Retention in Alzheimers Disease is an Early Event with Complex Relationship with CSF Biomarkers and Functional Parameters. <i>Current Alzheimer Research</i> , 2010, 7, 56-66.	1.4	100
10	Lower levels of the glial cell marker TSPO in drug-naive first-episode psychosis patients as measured using PET and [11C]PBR28. <i>Molecular Psychiatry</i> , 2017, 22, 850-856.	7.9	94
11	The immune response of the human brain to abdominal surgery. <i>Annals of Neurology</i> , 2017, 81, 572-582.	5.3	87
12	Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson's disease patients. <i>Journal of Clinical Investigation</i> , 2015, 125, 1339-1346.	8.2	83
13	Arterial Input Function Derived from Pairwise Correlations Between PET-image Voxels. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 1058-1065.	4.3	76
14	Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2006, 113, 205-218.	2.8	72
15	In vivo imaging of the 18-kDa translocator protein (TSPO) with [18F]FEDAA1106 and PET does not show increased binding in Alzheimer's disease patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 921-931.	6.4	71
16	Effects of age, BMI and sex on the glial cell marker TSPO – a multicentre [11C]PBR28 HRRT PET study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2329-2338.	6.4	70
17	Positron emission tomography imaging of the 18-kDa translocator protein (TSPO) with [18F]FEMPA in Alzheimer's disease patients and control subjects. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 438-446.	6.4	64
18	Reduced 5-HT1B receptor binding in the dorsal brain stem after cognitive behavioural therapy of major depressive disorder. <i>Psychiatry Research - Neuroimaging</i> , 2014, 223, 164-170.	1.8	61

#	ARTICLE	IF	CITATIONS
19	Unidirectional Influx and Net Accumulation of PIB. <i>Open Neuroimaging Journal</i> , 2008, 2, 114-125.	0.2	53
20	[11C]-PIB imaging in patients with Parkinson's disease: Preliminary results. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 345-347.	2.2	51
21	Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo. <i>Neurobiology of Aging</i> , 2011, 32, 2320.e15-2320.e32.	3.1	50
22	Long-term Effects of Galantamine Treatment on Brain Functional Activities as Measured by PET in Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 109-123.	2.6	50
23	The use of PIB-PET as a dual pathological and functional biomarker in AD. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 380-385.	3.8	49
24	In vivo evidence of a functional association between immune cells in blood and brain in healthy human subjects. <i>Brain, Behavior, and Immunity</i> , 2016, 54, 149-157.	4.1	48
25	Quantitative Analysis of <sup>18</sup> F-(E)-N-(3-Iodoprop-2-Enyl)-2 <sup>2</sup> -Carbofluoroethoxy-3 <sup>2</sup> -(4 <sup>2</sup> -Methyl-Phenyl) Nortropine Binding to the Dopamine Transporter in Parkinson Disease. <i>Journal of Nuclear Medicine</i> , 2015, 56, 714-720.	5.0	46
26	Assessment of simplified ratio-based approaches for quantification of PET [11C]PBR28 data. <i>EJNMMI Research</i> , 2017, 7, 58.	2.5	33
27	Extrastriatal dopamine D2-receptor availability in social anxiety disorder. <i>European Neuropsychopharmacology</i> , 2017, 27, 462-469.	0.7	31
28	Positron emission tomography imaging of 5-hydroxytryptamine1B receptors in Parkinson's disease. <i>Neurobiology of Aging</i> , 2014, 35, 867-875.	3.1	25
29	PET Molecular Imaging of Phosphodiesterase 10A: An Early Biomarker of Huntington's Disease Progression. <i>Movement Disorders</i> , 2020, 35, 606-615.	3.9	25
30	In vivo measurement of PDE10A enzyme occupancy by positron emission tomography (PET) following single oral dose administration of PF-02545920 in healthy male subjects. <i>Neuropharmacology</i> , 2017, 117, 171-181.	4.1	22
31	Distinct regional age effects on [11C]AZ10419369 binding to 5-HT 1B receptors in the human brain. <i>NeuroImage</i> , 2014, 103, 303-308.	4.2	21
32	Low serotonin1B receptor binding potential in the anterior cingulate cortex in drug-free patients with recurrent major depressive disorder. <i>Psychiatry Research - Neuroimaging</i> , 2016, 253, 36-42.	1.8	21
33	Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of selegiline. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 382-391.	6.4	21
34	5-HT <sub>1B</sub> receptor imaging and cognition: A positron emission tomography study in control subjects and parkinson's disease patients. <i>Synapse</i> , 2015, 69, 365-374.	1.2	19
35	Longitudinal Small-Animal PET Imaging of the zQ175 Mouse Model of Huntington Disease Shows In Vivo Changes of Molecular Targets in the Striatum and Cerebral Cortex. <i>Journal of Nuclear Medicine</i> , 2017, 58, 617-622.	5.0	19
36	Accuracy and reliability of [11C]PBR28 specific binding estimated without the use of a reference region. <i>NeuroImage</i> , 2019, 188, 102-110.	4.2	18

#	ARTICLE	IF	CITATIONS
37	Evidence of fatigue, disordered sleep and peripheral inflammation, but not increased brain TSPO expression, in seasonal allergy: A [ <sup>11</sup> C]PBR28 PET study. <i>Brain, Behavior, and Immunity</i> , 2018, 68, 146-157.	4.1	17
38	Low background and high contrast PET imaging of amyloid- $\beta^2$ with [ <sup>11</sup> C]AZD2995 and [ <sup>11</sup> C]AZD2184 in Alzheimer's disease patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 580-593.	6.4	16
39	[ <sup>11</sup> C]CHDI-626, a PET Tracer Candidate for Imaging Mutant Huntingtin Aggregates with Reduced Binding to AD Pathological Proteins. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 12003-12021.	6.4	15
40	CSF Biomarkers Correlate with Cerebral Blood Flow on SPECT in Healthy Elderly. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012, 33, 156-163.	1.5	14
41	$\beta^2$ -Amyloid binding in elderly subjects with declining or stable episodic memory function measured with PET and [ <sup>11</sup> C]AZD2184. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1507-1511.	6.4	4
42	Objective and Subjective Sleep in Rheumatoid Arthritis and Severe Seasonal Allergy: Preliminary Assessments of the Role of Sickness, Central and Peripheral Inflammation. <i>Nature and Science of Sleep</i> , 2021, Volume 13, 775-789.	2.7	2
43	Timing is everything: tau imaging across stages of Alzheimer's disease. <i>Brain</i> , 2020, 143, 2634-2636.	7.6	1
44	Follow-up study of amyloid deposition and glucose metabolism in patients with Alzheimer's disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S415-S415.	4.3	0